Key molecular lesions in colorectal and other cancers cause ␤-catenin-dependent transactivation of T cell factor (Tcf)-dependent genes. Disruption of this signal represents an opportunity for rational cancer therapy. To identify compounds that inhibit association between Tcf4 and ␤-catenin, we screened libraries of natural compounds in a high-throughput assay for immunoenzymatic detection of the protein-protein interaction. Selected compounds disrupt Tcf/␤-catenin complexes in several independent in vitro assays and potently antagonize cellular effects of ␤-catenin-dependent activities, including reporter gene activation, c-myc or cyclin D1 expression, cell proliferation, and duplication of the Xenopus embryonic dorsal axis. These compounds thus meet predicted criteria for disrupting Tcf/␤-catenin complexes and define a general standard to establish mechanism-based activity of small molecule inhibitors of this pathogenic protein-protein interaction.
Introduction
invariably disrupted in colorectal tumors and commonly affected by mutation in other cancers (de La Coste et al., 1998 ; Korinek Each year nearly 150,000 patients are diagnosed with colorectal et al., Morin et al., 1997; Rubinfeld et al., 1997 ; Satoh et cancer in the United States alone, and over 55, 000 Americans al., 2000) . The net result of these disruptions is stabilization of ␤-catenin, a multifunctional protein whose principal importance die of this disease (http://seer.cancer.gov). Besides surgical resection, which is rarely curative in advanced disease, current in cancers lies in its ability to bind Tcf/LEF family transcription factors to activate gene expression (van Noort and Clevers, therapy for colon cancer relies on traditional cytotoxic agents with limited effects. These considerations make it important to 2002). Gene targets of ␤-catenin-regulated transcription (CRT) include c-Myc and cyclin D1 (He et al., 1998 ; Shtutman et al., develop new treatments based on the appreciation of pathogenic molecular lesions. Mutations that drive colorectal cancer 1999; Tetsu and McCormick, 1999; van de Wetering et al., 2002) , which have plausible or demonstrated roles in malignancy. Beare among the best characterized of any human tumor Markowitz et al., 2002) and present opporcause colon cancer most frequently results from loss-of-function mutations in the APC gene ; tunities to fashion treatments based on biochemical mechanism. When a similar approach has been applied toward chronic Sparks et al., 1998) , which operates as a negative regulator immediately upstream of ␤-catenin, few signaling components myelogenous leukemia, a disease for which the defining molecular lesion is known, drug development has had a significant afford opportunities for pharmacologic intervention. Within this restricted field of candidates, the interaction between ␤-catenin impact on patient outcomes (Druker et al., 2001) .
The signaling pathway regulated by Wnt ligands, the adenoand Tcf/LEF factors represents a rational and feasible target for drug development. Tcf4 is the factor most prominently exmatous polyposis coli (APC)-axin complex, and ␤-catenin is pressed in colorectal cancers and also required for gut crypt stem cell differentiation (Korinek et al., 1998) . Tcf4/␤-catenin complexes determine cellular responses in part by controlling expression of c-Myc and p21 CIP1/WAF1 (van de Wetering et al., 2002) and signaling between EphrinB1 and its receptors EphB2 and EphB3 in the gut epithelium (Batlle et al., 2002) .
Recent studies reveal that tumors rely throughout their natural history on dysregulation imposed by early molecular lesions (Chin et al., 1999; Felsher and Bishop, 1999; Fisher et al., 2001) , and interference with CRT can revert transformed phenotypes in colon cancer. Deletion of the mutant ␤-catenin allele in HCT116 cells abrogates constitutive CRT and reduces cell growth and survival (Chan et al., 2002) , whereas overexpression of a dominant inhibitory form of Tcf4 induces G1 cell cycle arrest in Ls174T and DLD-1 cells, regardless of the presence of additional (e.g., Trp53) mutations (van de Wetering et al., 2002) . Suppression of CRT did not ostensibly affect DLD-1 cell growth in an independent study but restored epithelial cell polarity (Naishiro et al., 2001) . Thus, although consequences of dysregulated CRT remain under investigation, disrupting Tcf/ ␤-catenin complexes is likely to convey therapeutic benefit.
Here we report identification of low molecular weight compounds that disrupt Tcf/␤-catenin complexes. Using independent assays, we evaluate the specificity of inhibition and establish that two compounds function through the predicted mechanism in vitro and in vivo. The results illustrate an effective strategy to identify and test drugs directed against proteinprotein interactions, and they outline criteria for compounds to be regarded as antagonists of distal steps in the Wnt signaling pathway. Further refinements in drug design can build on these studies, possibly in conjunction with insights obtained from the crystal structure of Tcf4/␤-catenin (Graham et al., 2001; Poy et al., 2001 ) and alternative protein complexes. , 1996; Omer et al., 1999) . To identify inhibitors of this (violet asterisk), IkB kinase (green square), or ␤-catenin (blue diamond). The interaction, we developed a binding assay for high-throughput percent inhibition of ␤-catenin binding is expressed as a function of the concentration of soluble protein used as competitor. Only ␤-catenin bescreening (HTS). Purified ␤-catenin (amino acids 134-668) was haved competitively in this context. coated on microtiter plates and incubated sequentially with a Tcf4 fragment (residues 8-54) fused to glutathione-S-transferase (GST), anti-GST antibody, and alkaline phosphatase (AP)-conjugated secondary antibody ( Figure 1A ). Compounds that solvent for the chemical libraries, did not interfere with the assay disrupt the Tcf/␤-catenin complex thus register reduced AP (data not shown). Antagonism of Tcf4 binding by representative values relative to the background.
groups of chemicals showed a normal distribution, with 13% In surface plasmon resonance studies, ␤-catenin binding standard deviation (SD). These results support our use of a was significantly greater in the presence of tethered GST-Tcf4 nonhomogeneous, microplate-based binding assay to screen compared with unrelated GST-fusion proteins (data not shown). chemical libraries; we chose inhibition Ͼ3 SD of mean binding Four irrelevant proteins (histidine-tagged SMC1, SMC3 or I-B as the criterion for activity. kinase, and Hsp70) did not affect Tcf4/␤-catenin interaction
We screened approximately 7000 purified natural comat concentrations exceeding 100 g/ml, whereas soluble pounds from proprietary and public collections, initially at 10 ␤-catenin showed dose-dependent inhibition with IC 50 (concen-M concentrations. Eight compounds displayed reproducible, tration giving 50% of the maximal inhibition) ‫1ف‬ g/ml or 19 dose-dependent inhibition of the Tcf4/␤-catenin interaction with nM ( Figure 1B and data not shown), in agreement with previous estimates (Fasolini et al., 2003) . Dimethyl sulfoxide (DMSO), the IC 50 Ͻ 10 M, and their structures and purity were confirmed by The activity of six compounds in the ELISA, measured in confirmatory assays following the HTS, is expressed as the concentration (M) of compound required to inhibit the Tcf4/␤-catenin association by 50% (IC 50 ). Structures of two compounds that we did not characterize extensively and of two compounds used in specificity studies are shown in Supplemental Figure  S1 at http://www.cancercell.org/cgi/content/ full/5/1/91/DC1.
high-performance liquid chromatography and high-resolution tion of the compounds and/or the Tcf/␤-catenin complex with other proteins in the cell extracts or differences in target suscepmass spectrometry (Figure 2 and Supplemental Figure S1 at http://www.cancercell.org/cgi/content/full/5/1/91/DC1).
tibility between endogenous ␤-catenin and the shorter fragment used in the HTS. We also examined the effects of three potent This group of compounds shows diverse structural properties, although several of them share polyhydroxylated planar feacompounds on two other protein interactions, CyclinA-E2F1 (Shirodkar et al., 1992) and Bcl-xL/Bax (Yang et al., 1995) . Abtures; the stereochemistry, where shown, is taken from published studies (Takeda et al., 1988) . Six compounds are of microsence of inhibition of either complex ( Figure 3B and data not shown), other than a trivial decrease in CyclinA precipitation at bial origin: PKF115-584, CGP049090, and PKF222-815 were isolated from fungal organisms, whereas PKF118-744, PKF118-the highest concentration of PKF115-584, suggests that these chemicals do not disrupt protein interactions indiscriminately. 310, and ZTM000990 originated in Actinomycete strains. NPDDG39.024 was isolated from the marine sponge FascaplysiWe used electrophoretic mobility shift assays (EMSA) in nopsis reticulata (Jimenez et al., 1991) , and NPDDG1.024 deindependent biochemical tests of five compounds. EMSA poses rives from National Cancer Institute collections (NSC#618650-a challenge in colorectal cancer cells, where the abundance of F/1) without a listed source organism. We identified no additional Tcf factors and ␤-catenin restricts resolution of individual DNAactive molecules among 45,000 synthetic compounds from Noprotein complexes Morin et al., 1997) . vartis archival collections.
Although we could detect dose-dependent effects of small molIndividual compounds isolated in a single HTS are likely to ecules despite this limitation, protein targets were revealed more vary in tests of function and no single test may provide definitive clearly in transfected epithelial cells. Nuclear extracts from evidence of specific biological effects. We evaluated the activi-COS-7 cells transfected with Tcf4 and Flag epitope-tagged ties of six candidate compounds (Figure 2 ) in antagonizing ␤-catenin retarded gel migration of a Tcf-consensus DNA probe, ␤-catenin-dependent processes using a range of independent as expected, and four compounds completely blocked appearassays.
ance of the Tcf4/␤-catenin complex bound to DNA ( Figure 3C ). PKF118-744 and PKF118-310 did so selectively, whereas PKF222-815 and PKF115-584 interfered with the faster migratIndependent confirmation of disrupted Tcf/␤-catenin complexes ing complex between Tcf4 and DNA. The latter effect is independent of ␤-catenin, as it occurred when cells were transfected We incubated protein extracts from HCT116 colon cancer cells with compounds identified in the HTS and used a GST-Tcf4 only with Tcf4 or with a Tcf4 construct deleted for 53 N-terminal residues (data not shown). Whereas the results with PKF222-fusion protein to isolate ␤-catenin by affinity chromatography ( Figure 3A ). Three compounds (PKF115-584, CGP049090, and 815 and PKF115-584 are hence less informative with respect to higher-order Tcf complexes, they may suggest that these PKF222-815) eliminated binding and two others (PKF118-310 and NPDDG39.024) interfered measurably with ␤-catenin precompounds interact with Tcf4. Inhibition of ␤-catenin:Tcf4:DNA complexes by CGP049090, which is active in other biochemical cipitation. Active compounds showed dose-dependent inhibition, with IC 50 between 10 M and 30 M ( Figure 3B ). These tests ( Figure 3A ), was consistent but incomplete. None of the active agents blocked additional complexes data confirm the HTS results and reveal subtle differences in the efficiencies with which individual compounds score in the detected on the Tcf-consensus probe ( Figure 3C ), implying a degree of specificity in their action. To extend this specificity, two biochemical assays. These differences may reflect interac-we studied effects of the five compounds on other interactions. Association of pRb-E2F ( Figure 3D ) and PPAR␥-RXR (data not shown) complexes with their cognate DNAs was unaffected. Compounds identified in the HTS thus disrupt formation of Tcf/ ␤-catenin complexes with demonstrable specificity.
Inhibition of biological markers of Tcf4/␤-catenin transactivation
To investigate biologic activity of these compounds, we performed CRT reporter gene assays in HCT116 cells. Because cytotoxicity was evident over 72 hr of compound treatment (see below), we measured reporter gene activation at 24 hr. Moreover, we interpreted CRT results strictly in relation to the activity of a Tcf-independent ␤-galactosidase reporter, which served as an internal control for both DNA transfection efficiency and cell viability and was not impaired by any test compound. As expected, transient transfection of a firefly luciferase reporter regulated by three tandem Tcf-consensus binding sites yielded 60-fold induction relative to a control reporter mutated at each Tcf binding site (data not shown). Compounds isolated in the HTS inhibited reporter gene activation significantly ( Figure 4A ), whereas six independent control compounds, including some that resemble the test compounds in chemical structure, did not affect luciferase expression ( Figure 4A and data not shown). Inhibition of the reporter gene by the active compounds was dose dependent ( Figure 4B ). These results imply that compounds isolated in the HTS interfere with the targeted signaling pathway.
To extend these studies on expression of genes known to be regulated naturally by Tcf4 and ␤-catenin in human cells, we monitored levels of the CRT-responsive proteins Cyclin D1 and c-Myc (He et al., 1998; Shtutman et al., 1999; Tetsu and McCormick, 1999; van de Wetering et al., 2002) . We treated HCT116 cells with the compounds and assessed target expression levels by immunoblot analysis ( Figure 4B ). PKF115-584 and CGP049090 abrogated expression of both targets, whereas ZTM000990, PKF118-310, and NPDDG1.024 reduced levels of either c-Myc or cyclin D1; PKF118-744 did not affect either target ( Figure 4C ). No compound affected Cyclin E levels significantly, suggesting a selective effect on ␤-catenin targets. Although HCT116 cells carry the ␤-catenin ⌬S45 mutation, which prevents protein degradation (Liu et al., 2002; , conceivably the active compounds could activate some alternative pathway to destroy ␤-catenin. As evidence 
ure 4C).
HCT116 cell extracts were incubated in the absence (Ϫ) or presence (100 M) of the indicated compounds and recombinant GST-Tcf4 fusion protein. Precipitated ␤-catenin levels were assessed by SDS-PAGE and immunoblotting. Many ELISA-active compounds attenuated the Tcf4/␤-catenin interaction, whereas PKF115-584, CGP049090, and PKF222-815 abrogated binding totally.
radiolabeled Tcf-consensus oligonucleotide (lanes 1-10) or mutated (lane B: Inhibition of the interaction with GST-Tcf4 is dose dependent. Increasing 11) probes. All samples contained 1% DMSO. Nonspecific DNA-protein assoconcentrations (10, 30, and 100 M) of the indicated compounds inhibited ciations (NS) are revealed through the pattern seen with the mutated probe the Tcf4/␤-catenin interaction with increasing efficiency. Vehicle-treated (lane 11) or in the presence of excess (100ϫ) unlabeled probe (lane 3), sample (Ϫ) provides a control and little inhibition was observed for other and a supershifted complex is seen with inclusion of anti-Flag antibody in protein-protein interactions tested under identical conditions, including that the reaction (lane 4). This latter signal defines the Tcf4/␤-catenin complex between Cyclin A and the E2F1 transcription factor.
indicated by an arrow to the left and * to the right. C: Electrophoretic mobility shift assay (EMSA) with COS-7 cell extracts ex-D: Control EMSA with COS cell extracts expressing HA epitope-tagged retipressing full-length Tcf4 and Flag epitope-tagged ␤-catenin. 2.5 g of nunoblastoma protein pRb, showing binding to a radiolabeled probe specific clear extract expressing Tcf4, alone (lane 1) or mixed with 1.5 g of nuclear for E2F-family proteins, which are expressed endogenously. Experimental extract expressing exogenous ␤-catenin (lanes 2-10), were incubated with conditions and labeling of lanes and complexes is as indicated in B. Validation of inhibitor activity in vivo tein. Embryo fluorescence was the same with injection of the compounds as without ( Figure 5C ). To establish the specificity Early in Xenopus development, ␤-catenin accumulates on the prospective dorsal side (Larabell et al., 1997) ; accurate formaof inhibited ␤-catenin activity, we co-injected each compound with siamois mRNA, a target and immediate downstream eftion of a dorsal body axis requires nuclear ␤-catenin and activation of Tcf/␤-catenin target genes such as Siamois (Brannon et fector of Wnt signaling in Xenopus (Brannon et al., 1997) . Siamois's ability to induce a secondary dorsal axis was not affected al. , 1997) . Introducing ␤-catenin mRNA on the future ventral side activates the Wnt pathway ectopically and induces a secondary by any of the three compounds ( Figures 5D and 5E ). The active compounds thus disrupt axis duplication by interfering with body axis ( Figure 5B , compare ␤-catenin-injected tadpoles with untreated siblings). This developmental pathway thus provides ␤-catenin at a step proximal to Siamois activation and achieve their effects with minimal developmental toxicity. a rigorous means to test biologic effects of compounds that might target Tcf/␤-catenin compexes.
200 pg of ventrally expressed ␤-catenin mRNA induced dorTests for antiproliferative and Tcf-specific activities sal axis duplication in ‫%08ف‬ of embryos ( Figure 5A ). PKF222-Our results highlight the likely specific activity of two or three 815 and PKF118-744 had little or no effect, respectively, on this compounds in disrupting Tcf/␤-catenin complexes to predictresult (data not shown), even at doses that caused excessive able biologic effect. To profile cytotoxicity of the eight comembryo death. In contrast, co-injection of ␤-catenin mRNA with pounds isolated in our HTS, we assessed their effects on prolif-0.5 pmol PKF118-310, 3.5 pmol PKF115-584, or 0.25 pmol eration of HCT116 (mutant ␤-catenin, wild-type APC) and HT29 CGP049090 abrogated axis duplication almost completely, with (wild-type ␤-catenin, mutant APC) colon cancer cells (Ilyas et no contribution from the vehicle, DMSO ( Figure 5A ). Except for al. Sparks et al., 1998) . Six compounds inhibited cell a modest increase in embryo death rates with CGP049090, proliferation with IC 50 0.2-2 M in both cell lines; PKF222-815 toxic effects at these doses were not significant ( Figure 5A) , and NPDDG39.024 were less potent (Table 1) . Compared to and each compound restored normal tadpole development in only 1.3% of the natural compounds from this collection that induce apoptosis in HCT116 cells in vitro (Lee et al., 2003) , the most embryos ( Figure 5B ). The three compounds also failed to alter normal development through tadpole stages in the absence finding that so many compounds in this small group are cytotoxic is highly significant. Six other compounds derived from the of ectopic ␤-catenin (data not shown), which in part likely reflects limited cytoplasmic diffusion of injected molecules (Drummond same sources (e.g., ZTM002377 and CGP039329, structures shown in Supplemental Figure S1 at http://www.cancercell.org / et al., 1985) .
To exclude an effect resulting from interference with translacontent/full/5/1/91/DC1) did not inhibit growth of either cell line. If the active compounds interfere with Tcf/␤-catenin comtion of injected transcripts, we introduced each active compound together with mRNA encoding the green fluorescent proplexes in cells, they may be expected to show greater cytotoxic- ity toward carcinomas of the colon than those originating in shown). We therefore tested their activity against HCT116 subclones carrying deletion of either the wild-type or mutant other sites. Although excessive ␤-catenin signaling is suspected to contribute to tumorigenesis in tissues other than the intestine ␤-catenin allele (Chan et al., 2002) ; growth defects in clones lacking constitutive CRT are seen only at low cell densities, (Chesire et al., 2002; Lin et al., 2000; Mulholland et al., 2002) , we compared the activity of six compounds toward HCT116 which implies a limited role for ␤-catenin in cell replication, at least as measured in conventional assays. Parental HCT116 cells with that against PC-3 and DU-145 prostate cancer cells. Cytotoxicity from three compounds was nonselective, whereas cells and the KO58 derivative bearing the constitutively active ␤-catenin allele responded similarly to treatment with PKF115-PKF222-815, PKF115-584, and CGP049090 showed 3-to 8-fold lower IC 50 for colon cancer cells (Table 1) . The latter 584, whereas DO20 cells with a wild-type ␤-catenin allele appeared more sensitive ( Figure 6A ). All three clones showed simitwo molecules also showed Ͼ2-fold higher IC 100 toward both prostate-derived lines than against HCT116 cells (data not lar responses to CGP049090 and compound-induced apoptosis with both compounds, as judged by nuclear condensation (DAPI rupt the typically large and hydrophobic interface between interacting proteins (Cochran, 2001; Toogood, 2002) . However, critistaining not shown).
␤-catenin is essential for many cellular processes. Associacal cellular functions rely on protein associations, and neglecting this reality in drug discovery is needlessly limiting. Drugs with tions with membrane bound E-cadherin and with APC mediate homotypic cell adhesion and ␤-catenin stability, respectively, established value in treating cancer or other diseases are known to target essential protein-protein interactions, including the through domains that overlap with Tcf binding armadillo repeats (Graham et al., 2000; Huber and Weis, 2001 ); this overlap previnca alkaloid inhibitors of tubulin dimerization (Owellen et al., 1976) . Recent studies show that other protein-protein interacsents a potential obstacle in developing selective drugs (Huber and Weis, 2001 ). To evaluate specificity of the active chemicals, tions are also vulnerable to small-molecule interference (Berg et al., 2002; Chen et al., 2002) and define allosteric interactions we determined their effect on the presence of E-cadherin and APC in ␤-catenin immunoprecipitates from HCT116 and HT29 between drug candidates and their target proteins (Arkin et al., 2003; Baba et al., 1999) . Protein associations commonly rely colon cancer cells, respectively. Although three compounds (PKF222-815, PKF115-584, and CGP049090) reduced the effion a few key residues and the Tcf/␤-catenin complex is no exception, as revealed by crystal structure and in the deleterious ciency of ␤-catenin immunoprecipitation (see lower relative intensities of both the immunoglobulin and ␤-catenin bands in consequences of single point mutations (Fasolini et al., 2003; Graham et al., 2000 Graham et al., , 2001 Knapp et al., 2001 ; Omer et al., Figure 6B ), the E-cadherin:␤-catenin ratio remained constant ( Figure 6C ), whereas these compounds eliminated the interac-1999; Poy et al., 2001) . Small molecule antagonists hence need to interfere mainly with critical amino acid contacts, and modest tion with APC. These results highlight the challenge in selective antagonism of Tcf/␤-catenin complexes and suggest that ratiodisruption of the binding equilibrium could have significant outcomes. nal drug design may need to exploit the known subtle differences between ␤-catenin's interactions with Tcf and with proWe therefore sought to identify natural products that disrupt interactions between Tcfs and ␤-catenin. To confirm that isoteins like APC (Eklof Spink et al., 2001) . lated compounds function as predicted, we tested their ability to inhibit CRT in vitro and in vivo. As expected, six lead compounds Discussion function differently in various secondary assays, albeit with a correlation between their activities in tests of protein interaction, Molecular pathways of tumorigenesis present opportunities for cell proliferation, and CRT (Table 2) . Two fungal derivatives targeted therapy. This is illustrated well by the utility of Abl (PKF115-854 and CGP049090) fulfill nearly every tested predickinase or epidermal growth factor receptor antagonists in treattion, including disruption of Tcf/␤-catenin complexes in vitro and ing chronic myeloid leukemia and breast cancer, respectively inhibition of colon cancer cell proliferation, CRT, and ␤-catenin- (Druker et al., 2001; Pegram et al., 1998) . The mutations implimediated axis duplication in Xenopus embryos. These comcated in colon cancer pathogenesis (Kinzler and Vogelstein, pounds are close analogs of each other and their effects may 1996) confer constitutive CRT and high nuclear ␤-catenin levels occur through the common core structure. This structure does, (Anderson et al., 2002; Korinek et al., 1997; Morin et al., 1997) . Previous attempts to exploit these properties through gene tarhowever, raise the possibility of their aggregating in solution, which can generate false positive results in chemical screens geting or antisense strategies (Green et al., 2001; Kwong et al., 2002) validate the seminal role of ␤-catenin in colon cancer, but (McGovern et al., 2002) . By nuclear magnetic resonance imaging, these molecules did not self-aggregate in several aquetheir promise is limited by fundamental barriers to gene-based treatments. Small molecules that target individual components ous buffers but did so in solutions containing 0.1% Nonidet-P40 detergent (data not shown). While this may account in part distally in the APC pathway could bypass these limitations, and ␤-catenin's interaction with Tcf4 represents one such target.
for the effects we observed in affinity chromatography studies (Figure 3 ), molecular aggregates cannot be implicated in our Small molecules are commonly considered ill-suited to dis-results with nonaggregating buffers in embryos, cells, and nuclear extracts. Moreover, these compounds passed rigorous tests for biochemical specificity, and the weight of evidence points to effects occurring through the targeted mechanism of ␤-catenin-protein interactions.
The molecular mechanisms by which the isolated compounds interfere with the targeted interaction are unclear. In the future, it will be important to map their docking sites within ␤-catenin and/or Tcf, a goal in which we have met with limited success to date. Meanwhile, the observation that three compounds also interfere with APC/␤-catenin complexes suggests that their actions are mediated through ␤-catenin. Two compounds that disrupt the Tcf4/␤-catenin complex (PKF115-584 and PKF222-815) also prevent association of Tcf proteins with DNA. Possibly, these compounds interact additionally with DNA, as occurs with many small molecules, or modulate Tcf4 allosterically and less specifically. PKF115-584, whose structure corresponds to that of calphostin C, is known to inhibit protein kinase C (Kobayashi et al., 1989) , but the role of PKC in colon cancer is unclear. Expression of the ␣ isoform is reduced in colon cancer cells, hinting at the possibility of a tumor suppressor function (Assert et al., 1999) , whereas PKC␤II expression increases early in experimental colon tumors in rodents and PKC␤II transgenic mice show colonic epithelial hyperproliferation (Gokmen-Polar et al., 2001; Murray et al., 1999) . PKC also inhibits GSK3-␤ (Cook et al., 1996) , the enzyme that targets ␤-catenin for degradation (Rubinfeld et al., 1996; Yost et al., 1996) . Indeed, calphostin C promotes GSK3-␤ effects and impairs Wnt-induced accumulation of ␤-catenin (Chen et al., 2000) , although other PKC antagonists exert opposite effects (Orford et al., 1997) . Whereas inhibition of PKC could potentially contribute to PKF115-584 activity, our biochemical and Xenopus data clearly point to independent effects on Tcf/␤-catenin complexes; a combination of the two properties may explain the high potency of this compound in some assays. Conversely, our results offer an alternative interpretation to the previous finding of calphostin effects on Wnt signaling (Chen et al., 2000) , which may have resulted from disrupted Tcf/␤-catenin complexes. Various inhibitors of the ␤-catenin pathway could thus be useful in studying CRT in normal cellular processes, including cell growth and replication.
Differences in cell growth between HCT116 cells bearing deletions of different ␤-catenin alleles are apparent only at low cell densities (Chan et al., 2002) , and alternative means of suppressing CRT affect growth of the DLD-1 cell line differently (Naishiro et al., 2001; van de Wetering et al., 2002) . Conventional cytotoxic agents. 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; GST, precipitation by glutiathone-S-transferase-tethered Tcf4; EMSA, electrophoretic mobility shift assay; MTS, cell proliferation assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; RGA, luciferase reporter gene activation. Activities are rated relative to other tested compounds (NT, not tested) according to the following scheme for ϩϩ and ϩ ratings, respectively: IC 50 Ͻ 3 M or Ն 3 M in the ELISA, IC 50 Ͻ 1 M or Ն 1 M in one or both cell lines in the cell proliferation (MTS) and reporter gene (RGA) assays, inhibition achieved with 0.5 M compound or only at the 5 M concentration for the endogenous CRT targets c-Myc and cyclin D1, and Ͼ80% or 50%-80% inhibition of axis duplication in Xenopus embryos.
plates were incubated sequentially with goat anti-GST antibody (Amersham ␤-catenin interacts with several proteins, including E-cadh- ( Drummond et al., 1985) . Indeed, these compounds also disrupt cellular ␤-catenin/APC complexes, supporting the speculation demonstrates that some small molecules can disrupt these (Lee et al., 1999) Precipitation of cellular proteins and immunoblot analysis GST-Tcf4 and untagged human ␤-catenin were prepared as described pre-GST-Tcf4, GST-E2F1(1-171), and GST-Bcl-xL(135-775) fusion proteins were viously (Poy et al., 2001 ) to estimated purities Ͼ90%. For specificity studies, purified from E. coli BL21 lysates by affinity chromatography with glutathi6XHis-SMC1, 6XHis-SMC3, 6XHis-IB kinase, and untagged Hsc70 were one-sepharose followed either by cation-exchange chromatography or dialpurified from baculovirus-infected Sf9 cells and diluted in Dulbecco's PBS ysis in PBS. HCT116 lysates (125 g protein in buffer A containing 50 mM (GIBCO-BRL). CM-5 sensor chips (Biacore Inc., Piscataway, NJ) were coated Tris [pH 8.0], 250 mM NaCl, 0.1% NP-40, 5 mM EDTA, 10% glycerol, 0.1 with goat anti-GST antibody (Amersham Biosciences) using the Biacore BRmM sodium vanadate, 1 mM aprotinin, 1 mM leupeptin, 50 mM NaF, 1 mM 1002-23a kit for GST fusion protein capture. Following injection of either phenylmethyl sulfonyl fluoride) were incubated with various concentrations control or GST-Tcf4 (5 l at 20 g/ml) onto separate quadrants of the sensor of compounds and 5 g GST-fusion proteins overnight at 4ЊC. Samples chip, ␤-catenin (5 l at 160 g/ml) was introduced to assess specificity of were immobilized on glutathione-sepharose A beads (Amersham Pharmacia) protein-protein interactions.
for 2 hr at 4ЊC, washed 3 times in buffer B containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP-40, and 1 mM EDTA, and the retained material was Compound libraries and high-throughput ELISA eluted in SDS-PAGE buffer and resolved in 8% polyacrylamide gels for Approximately 6,000 purified natural products and 45,000 synthetic comimmunoblot analysis. Cyclin A (H432) and Bax (N20) antibodies (Ab) were pounds originated in Novartis collections, and 1,000 pure natural products from Santa Cruz Laboratories and ␤-catenin Ab (C19220) was from Transwere provided through the Natural Product Collaborative Drug Discovery duction Laboratories. Separately, HCT116 cells were seeded at 10 6 cells/ Group (NPCDDG). Nunc-Immuno MaxiSorp Plates (Nunclon) were coated plate, cultured overnight at 37ЊC, treated with compounds (0.5-5 M) for with 5 g/ml purified ␤-catenin fragment in phosphate-buffered saline (PBS); 24 hr, and washed. Cells were lysed in buffer A and 50 g protein was nonspecific binding was assessed in uncoated wells. Plates were washed resolved by SDS-PAGE. Relative protein levels were judged by immunoblot 8 times with TBST (50 mM Tris [pH 8.0], 0.15 M NaCl, 0.05% Tween-20), using ␤-catenin, cyclin D1 (SC753, Santa Cruz), c-Myc (Ab1, Oncogene blocked for 2 hr at 4ЊC with SuperBlock (Pierce), washed with TBST, incuResearch Products), or cyclin E (SC247, Santa Cruz) Ab and enzymatic bated for 2 hr at 4ЊC with 1 g/ml purified GST-Tcf4 in the presence of 10 chemiluminescence (Amersham Pharmacia). Finally, HT29 and HCT116 M compounds diluted in assay buffer (50 mM Tris [pH 8.0], 0.15 M NaCl, whole-cell extracts prepared in buffer C (140 mM NaCl, 20 mM Tris [pH 8], 0.05% Tween-20, 2% bovine serum albumin) with a final concentration of 1% DMSO, followed by 8 washes in TBST. To detect bound GST-Tcf4, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 10% glycerol) were precleared with protein G beads (Amersham Pharmacia), incubated with DMSO or mRNA was performed similarly and fluorescence was assessed after 36 hr at stage 25. compounds at 30 M for 4 hr at 4ЊC, and treated with 4 g mouse ␤-catenin Ab (BD Biosciences) at 4ЊC overnight, followed by 20 l protein G slurry and 3 washes in buffer C. Precipitates were resolved on Tris-acetate gels Acknowledgments (GIBCO) and immunoblotted with E-cadherin (BD Biosciences) . The probe sequence for control E2F binding is published (Cobrinik et al., 1993) . Binding was performed in 30 l buffer (60 mM KCl, 1 mM EDTA, 1 mM DTT, 4 mg/l poly-deoxyinosine-deoxycytidine and 10% glycerol). Tcf4 (2.5 g) and ␤-catenin (1.5 g) nuclear extracts were Sci. USA 100, 1603-1608. solution (2 mg/ml). Cells were incubated in 10 l of this solution at 37ЊC for 3 hr and A 490 was measured. The effect of each compound is expressed as Assert, R., Kotter, R., Bisping, G., Scheppach, W., Stahlnecker, E., Muller, the concentration required to reduce A 490 by 50% (IC 50 ) relative to vehicle-K.M., Dusel, G., Schatz, H., and Pfeiffer, A. (1999) . Anti-proliferative activity treated cells or to return A 490 to the level present at t ϭ 0, before addition of protein kinase C in apical compartments of human colonic crypts: eviof compounds (IC 100 ).
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